June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Efficacy of two-month treatment with cord blood serum eye drops in severe dry eye patients: an in vivo confocal microscopy study.
Author Affiliations & Notes
  • Giuseppe Giannaccare
    DIMES, University of Bologna, Bologna, Italy
  • Piera Versura
    DIMES, University of Bologna, Bologna, Italy
  • Marina Buzzi
    Emilia Romagna Cord Blood Bank-Transfusion Service, Alma Mater Studiorum University of Bologna and S.Orsola-Malpighi Teaching Hospital, Bologna, Italy, Bologna, Italy
  • Michela Fresina
    DIMES, University of Bologna, Bologna, Italy
  • Claudio Velati
    Emilia Romagna Cord Blood Bank-Transfusion Service, Alma Mater Studiorum University of Bologna and S.Orsola-Malpighi Teaching Hospital, Bologna, Italy, Bologna, Italy
  • Emilio C Campos
    DIMES, University of Bologna, Bologna, Italy
  • Footnotes
    Commercial Relationships   Giuseppe Giannaccare, None; Piera Versura, None; Marina Buzzi, None; Michela Fresina, None; Claudio Velati, None; Emilio Campos, None
  • Footnotes
    Support  The present work was supported by two Research Grants obtained from ‘‘Fondazione Cassa di Risparmio di Bologna” (Bologna, Italy) and ‘‘Beneficientia Stiftung” (Vaduz, Liechtenstein).
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 3925. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Giuseppe Giannaccare, Piera Versura, Marina Buzzi, Michela Fresina, Claudio Velati, Emilio C Campos; Efficacy of two-month treatment with cord blood serum eye drops in severe dry eye patients: an in vivo confocal microscopy study.. Invest. Ophthalmol. Vis. Sci. 2017;58(8):3925.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The efficacy of cord blood serum (CBS) eye drops in the treatment of dry eye (DE) patients has been demonstrated by the decrease of ocular surface staining and the improvement of discomfort symptoms. No data are available about in vivo analysis of corneal cell morphology, and specifically of corneal nerves. The purpose of this study was to investigate for the first time corneal nerve changes by in vivo confocal microscopy (IVCM) after 2-month treatment with CBS eye drops in severe DE patients.

Methods : Twenty DE patients (13 females, 7 males; mean age 61.1±12.6 yrs; DEWS severity level 3-4) not responding to conventional therapy were treated in both eyes with CBS eye drops 8 times daily for 2 months, and included in this prospective study. The following parameters were evaluated before (T0 baseline) and after (T1) treatment: subjective symptoms scored by Ocular Surface Disease Index (OSDI) and Visual Analogue Scale (VAS), corneal vital staining graded by Oxford Scale and IVCM performed in the central corneal area for the analysis of giant epithelial cells (GECs), sub-basal nerve density and tortuosity, neuromas, dendritic cell (DC) density. Data were expressed as mean ± standard deviation. Paired Student’s t-test was used to compare values pre- and post-treatment, and correlation among parameters was calculated by Spearman’s rho (significance p<0.05).

Results : OSDI, VAS and Oxford grading values significantly decreased after treatment compared to baseline (respectively, 44.1±18.9 vs 74.2±13.9, 3.7±1.5 vs 8.9±0.9 and 2.4±1.1 vs 3.3±1.3; always p<0.0001). Corneal nerve morphology improved at T1 vs T0 with specific reference to higher nerve density (respectively, 3.38±1.56 vs 2.55±1.62; p<0.001) and lower nerve tortuosity (fig. 1-2) (2.99±0.72 vs 3.47±0.65; p<0.01). GECs and neuromas were reduced at T1 vs T0, respectively from 32% to 20% and from 67.5% to 15% of eyes. No significant variation in the DC density was found at T1 vs T0 (respectively 162.62±162.11 vs 154.76±147.67 cell/mm2; p=0.5). OSDI reduction was correlated with neuromas and DCs at baseline (respectively, rho=0.319 and 0.435; p<0.001).

Conclusions : CBS eye drops significantly improved both corneal nerve morphology and subjective symptoms in severe DE patients. Increasing dendritic cell density and presence of neuromas at baseline were correlated to a greater reduction of symptoms after treatment.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×